Home Newsfeeds Revelation Biosciences Q2 EPS $(0.12)

Revelation Biosciences Q2 EPS $(0.12)

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.12) per share.

byMichael Horton

August 15, 2022

1 minute read

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.12) per share.

Needham Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $40

By Benzinga Newsdesk

December 14, 8:39 AM

Needham analyst Ami Fadia initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy rating and announces Price Target of $40.

DAWN

Piper Sandler Maintains Neutral on Fastly, Raises Price Target to $14

By Benzinga Newsdesk

February 16, 11:11 AM

Piper Sandler analyst James Fish maintains Fastly (NYSE:FSLY) with a Neutral and raises the price target from $10 to $14.

FSLY

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

By Benzinga Newsdesk

October 14, 6:25 AM

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.

HRMY

Bitcoin, Ethereum, Dogecoin Drop After Fake News Of Spot ETF Approval — $200M Worth of Liquidations Follow: Analyst Warns Of Fakeout Rallies, Looming Corrections For King Crypto

By Mehab Qureshi

January 9, 10:30 PM

During Tuesday’s trading session, major cryptocurrencies experienced significant fluctuations due to a false social media post by the Securities and Exchange Commission (SEC) regarding the approval of spot

$BONK

Revelation Biosciences Q2 EPS $(0.12)

Related Posts

Needham Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $40

Piper Sandler Maintains Neutral on Fastly, Raises Price Target to $14

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Bitcoin, Ethereum, Dogecoin Drop After Fake News Of Spot ETF Approval — $200M Worth of Liquidations Follow: Analyst Warns Of Fakeout Rallies, Looming Corrections For King Crypto